Segment, Product and Geographic Area Information (Tables)

9 Months Ended

Oct. 02, 2011

Schedule of Segment Reporting Information by Segment [Table Text Block]

Certain information by operating segment follows:

	Revenues				R&D Expenses				Earnings(a)
(millions of dollars)	Oct. 2, 2011		Oct. 3, 2010		Oct. 2, 2011		Oct. 3, 2010		Oct. 2, 2011			Oct. 3, 2010
Three Months Ended:
Primary Care	$	5,948	$	5,653	$	285	$	353	$	4,156		$	3,817
Specialty Care and Oncology		4,131		4,052		400		388		2,678			2,730
Established Products and Emerging Markets		4,668		4,240		71		100		2,432			2,158
Animal Health and Consumer Healthcare		1,815		1,533		97		93		595			423
Total reportable segments		16,562		15,478		853		934		9,861			9,128
Nutrition and other business activities(b)		631		517		844		861		(697	)		(749	)
Reconciling Items:
Corporate(c)		––		––		337		360		(1,866	)		(1,893	)
Purchase accounting adjustments(d)		––		––		––		8		(1,711	)		(1,625	)
Acquisition-related costs(e)		––		––		5		25		(301	)		(792	)
Certain significant items(f)		––		––		149		––		(1,310	)		(2,413	)
Other unallocated(g)		––		––		––		––		(307	)		(242	)
	$	17,193	$	15,995	$	2,188	$	2,188	$	3,669		$	1,414
Nine Months Ended:
Primary Care	$	17,259	$	17,442	$	912	$	1,128	$	11,513		$	11,954
Specialty Care and Oncology		12,407		12,054		1,122		1,129		8,137			8,120
Established Products and Emerging Markets		13,945		13,976		206		197		7,397			8,074
Animal Health and Consumer Healthcare		5,318		4,613		304		296		1,598			1,302
Total reportable segments		48,929		48,085		2,544		2,750		28,645			29,450
Nutrition and other business activities(b)		1,750		1,618		2,568		2,630		(2,178	)		(2,270	)
Reconciling Items:
Corporate(c)		––		––		998		1,142		(5,553	)		(5,911	)
Purchase accounting adjustments(d)		––		––		––		23		(5,232	)		(6,564	)
Acquisition-related costs(e)		––		––		9		45		(1,471	)		(2,692	)
Certain significant items(f)		––		––		397		––		(3,176	)		(2,691	)
Other unallocated(g)		––		––		––		––		(566	)		(833	)
	$	50,679	$	49,703	$	6,516	$	6,590	$	10,469		$	8,489

(a) Income from continuing operations before provision for taxes on income.

(b) Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

(c) Corporate for R&D expenses includes, among other things, administration expenses and share-based compensation expenses associated with our research and development activities and for Earnings includes, among other things, administration expenses, interest income/(expense) and all share-based compensation expenses.

(d) Purchase accounting adjustments include charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

(e) Acquisition-related costs can include costs associated with acquiring businesses and integrating and restructuring acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity for additional information).

(f) Certain significant items are substantive, unusual items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments.

For the third quarter of 2011, certain significant items for R&D expenses includes implementation costs and additional depreciation-asset restructuring associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, and for Earnings includes (i) restructuring charges and implementation costs of $1.1 billion associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, (ii) charges for certain legal matters of $132 million and (iii) certain asset impairment charges of $105 million (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions––Net for additional information).

For the third quarter of 2010, certain significant items for Earnings includes (i) asset impairment charges of $1.5 billion (ii) charges for certain legal matters of $701 million and (iii) Wyeth-related inventory write-off of $212 million (which included a purchase accounting fair value adjustment of $104 million), primarily related to biopharmaceutical inventory.

For the first nine months of 2011, certain significant items for R&D expenses includes implementation costs and additional depreciation-asset restructuring associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, and for Earnings includes (i) restructuring charges and implementation costs of $1.9 billion associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, (ii) charges for certain legal matters of $657 million and (iii) certain asset impairment charges of $582 million (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions––Net for additional information).

For the first nine months of 2010, certain significant items for Earnings includes (i) asset impairment charges of $1.7 billion, (ii) charges for certain legal matters of $843 million and (iii) Wyeth-related inventory write-off of $212 million (which included a purchase accounting fair value adjustment of $104 million), primarily related to biopharmaceutical inventory.

(g) Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.

Schedule of Revenue by Products [Table Text Block]

Significant product revenues follow:

	Three Months Ended				Nine Months Ended
(millions of dollars)	Oct. 2, 2011		Oct. 3, 2010		Oct. 2, 2011		Oct. 3, 2010
Revenues from biopharmaceutical products:
Lipitor	$	2,602	$	2,534	$	7,578	$	8,104
Prevnar/Prevenar 13		1,006		735		2,823		1,590
Enbrel(a)		957		799		2,741		2,409
Lyrica		961		757		2,695		2,242
Celebrex		643		578		1,856		1,752
Viagra		493		459		1,458		1,429
Norvasc		350		330		1,081		1,120
Zyvox		321		285		965		876
Xalatan/Xalacom		277		416		960		1,287
Sutent		298		257		870		771
Premarin family		267		263		757		779
Geodon/Zeldox		263		262		753		763
Detrol/Detrol LA		213		237		668		758
Genotropin		215		211		654		650
Vfend		171		200		558		595
Chantix/Champix		156		163		545		522
Effexor XR		165		175		537		1,512
BeneFIX		178		156		518		474
Zosyn/Tazocin		149		255		490		749
Caduet		150		127		435		388
Pristiq		146		118		422		341
Zoloft		139		126		420		390
Prevnar/Prevenar (7-valent)		98		179		406		1,030
Revatio		140		116		393		352
Medrol		127		119		383		341
ReFacto AF/Xyntha		140		102		380		290
Zithromax/Zmax		93		90		335		303
Aricept(b)		117		106		335		337
Aromasin		85		111		294		361
Cardura		92		95		289		312
Rapamune		96		104		285		292
Fragmin		95		84		283		258
BMP2		83		101		277		298
Relpax		86		75		250		239
Xanax XR		77		72		232		224
Tygacil		76		78		224		250
Neurontin		67		80		222		238
Diflucan		72		74		201		205
Arthrotec		61		61		182		185
Unasyn		58		61		172		182
Protonix		65		203		168		535
EpiPen(c)		59		-		160		-
Sulperazon		51		49		155		153
Skelaxin(c)		58		-		145		-
Inspra		51		37		142		113
Dalacin/Cleocin		51		54		139		168
Alliance revenues(d)		919		1,042		2,678		3,107
All other biopharmaceutical products		1,710		1,409		5,097		4,198
Total revenues from biopharmaceutical products		14,747		13,945		43,611		43,472
Revenues from other products:
Animal Health		1,041		860		3,078		2,599
Consumer Healthcare		774		673		2,240		2,014
Nutrition		577		441		1,540		1,375
Pfizer CentreSource		54		76		210		243
Total revenues	$	17,193	$	15,995	$	50,679	$	49,703

(a) Outside the U.S. and Canada.

(b) Represents direct sales under license agreement with Eisai Co., Ltd.

(c) Legacy King product. King’s results are included in our financial statements commencing from the acquisition date of January 31, 2011, in accordance with Pfizer’s domestic and international year-ends. Therefore, our results for both periods in 2010 do not include King’s results of operations.

(d) Enbrel (in the U.S. and Canada), Aricept, Exforge, Rebif and Spiriva.

Schedule of Revenues by Geographic Area [Table Text Block]

Revenues by geographic area follow:

	Three Months Ended							Nine Months Ended
(millions of dollars)	Oct. 2, 2011		Oct. 3, 2010		% Change			Oct. 2, 2011		Oct. 3, 2010		% Change
Revenues
United States	$	6,879	$	7,063		(3	)	$	20,603	$	21,661		(5	)
Developed Europe(a)		4,074		3,762		8			12,223		12,079		1
Developed Rest of World(b)		2,840		2,349		21			8,059		7,344		10
Emerging Markets(c)		3,400		2,821		21			9,794		8,619		14
Total Revenues	$	17,193	$	15,995		7		$	50,679	$	49,703		2

(a) Developed Europe region includes the following markets: Western Europe and the Scandinavian countries.

(b) Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.

(c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Middle East, Africa, Central and Eastern Europe and Turkey.